REAL-WORLD EFFECTIVENESS OF MET TKIS VERSUS PEMBROLIZUMAB ± CHEMOTHERAPY (PEMBRO±CT) IN 1L FOR PATIENTS WITH MET EXON 14 SKIPPING ALTERATIONS IN LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN THE US
Author(s)
Mo Yang, PhD1, Joanna Harton, PhD2, Yun-Ting Yen, PhD3, Chris P. Pescott, MSc, MD4, Amy Phillips, PharmD5, Paul K. Paik, MD6.
1Director, EMD Serono Inc. - Rockland, MA, Boston, MA, USA, 2Genesis Research Group, Groton, MA, USA, 3Genesis Research Group, New Brunswick, NJ, USA, 4Merck Healthcare KGaA, Darmstadt, Germany, 5EMD Serono, Inc., Chattanooga, TN, USA, 6Thoracic Oncology Service,, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
1Director, EMD Serono Inc. - Rockland, MA, Boston, MA, USA, 2Genesis Research Group, Groton, MA, USA, 3Genesis Research Group, New Brunswick, NJ, USA, 4Merck Healthcare KGaA, Darmstadt, Germany, 5EMD Serono, Inc., Chattanooga, TN, USA, 6Thoracic Oncology Service,, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
OBJECTIVES: To evaluate real-world outcomes in patients with advanced/metastatic NSCLC harboring MET exon 14 skipping alterations (METex14) treated in first-line (1L) with MET TKIs (tepotinib/capmatinib) versus pembro±CT in the US.
METHODS: This retrospective cohort study used the ConcertAI PATIENT360™ US database to identify adults with METex14 skipping stage IIIB-IV or advanced/metastatic NSCLC initiating 1L MET TKIs or pembro±CT between February 1, 2021 and October 30, 2024. Outcomes included real-world response rate (rwRR), progression-free survival (rwPFS), overall survival (rwOS), time to discontinuation (rwTTD), and time to next treatment (rwTTNT). Propensity score weighting was applied to balance baseline characteristics. Time-to-event outcomes were analyzed using weighted Kaplan-Meier and Cox proportional hazards models.
RESULTS: Among 273 eligible patients, 179 received MET TKIs (96 in 1L). Balancing baseline characteristics using propensity score weighting, yielded an effective sample size for pembro±CT of 23.76. Median follow-up (months) was 11.8 (0.3-43.3) for MET TKIs vs 18.2 (0.6-40.0) for pembro±CT. rwRR was comparable for MET TKIs (0.48 [95% CI: 0.36-0.61]) vs pembro±CT (0.48 [0.24-0.72]; p=0.97). Median rwPFS was 7.9 (5.1-10.1) vs 4.9 (3.1- not estimable [NE]) months (HR: 1.15 [0.62-2.13]; p=0.66) and median rwOS was 14.5 (11.4-25.2) for MET TKIs vs 18.3 (17.6-NE) months (HR: 0.70 [0.37-1.30]; p=0.26), for pembro±CT. MET TKIs were associated with numerically longer rwTTD (6.4 [4.9, 8.2] vs 3.9 [3.3, 5.6] months) and rwTTNT (13.0 [11.3, 20.7] vs 5.6 [3.9, 25.5] months).
CONCLUSIONS: No statistically significant differences were observed between these US-based cohorts. MET TKIs showed numerically longer rwPFS and treatment persistence, while pembro±CT showed numerically longer rwOS. Overall effectiveness was comparable, supporting MET TKIs as an effective and clinically meaningful 1L option in METex14 skipping NSCLC. Limitations include small, weighted samples, disproportionate follow-up, missing data, response assessment variability, and limited generalizability.
METHODS: This retrospective cohort study used the ConcertAI PATIENT360™ US database to identify adults with METex14 skipping stage IIIB-IV or advanced/metastatic NSCLC initiating 1L MET TKIs or pembro±CT between February 1, 2021 and October 30, 2024. Outcomes included real-world response rate (rwRR), progression-free survival (rwPFS), overall survival (rwOS), time to discontinuation (rwTTD), and time to next treatment (rwTTNT). Propensity score weighting was applied to balance baseline characteristics. Time-to-event outcomes were analyzed using weighted Kaplan-Meier and Cox proportional hazards models.
RESULTS: Among 273 eligible patients, 179 received MET TKIs (96 in 1L). Balancing baseline characteristics using propensity score weighting, yielded an effective sample size for pembro±CT of 23.76. Median follow-up (months) was 11.8 (0.3-43.3) for MET TKIs vs 18.2 (0.6-40.0) for pembro±CT. rwRR was comparable for MET TKIs (0.48 [95% CI: 0.36-0.61]) vs pembro±CT (0.48 [0.24-0.72]; p=0.97). Median rwPFS was 7.9 (5.1-10.1) vs 4.9 (3.1- not estimable [NE]) months (HR: 1.15 [0.62-2.13]; p=0.66) and median rwOS was 14.5 (11.4-25.2) for MET TKIs vs 18.3 (17.6-NE) months (HR: 0.70 [0.37-1.30]; p=0.26), for pembro±CT. MET TKIs were associated with numerically longer rwTTD (6.4 [4.9, 8.2] vs 3.9 [3.3, 5.6] months) and rwTTNT (13.0 [11.3, 20.7] vs 5.6 [3.9, 25.5] months).
CONCLUSIONS: No statistically significant differences were observed between these US-based cohorts. MET TKIs showed numerically longer rwPFS and treatment persistence, while pembro±CT showed numerically longer rwOS. Overall effectiveness was comparable, supporting MET TKIs as an effective and clinically meaningful 1L option in METex14 skipping NSCLC. Limitations include small, weighted samples, disproportionate follow-up, missing data, response assessment variability, and limited generalizability.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO164
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment, Comparative Effectiveness or Efficacy
Disease
Oncology, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)